


**Chronic & Incurable diseases
need for adequate novel drug molecules**



Direct economic healthcare costs
for treating diseases worldwide are
\$ 5 Trillion

Micar21



**R&D drug discovery factory
for novel drug small molecule
Investment opportunities**

Micar21 strength




nature

SCIENTIFIC
REPORTS

Micar21 Drug Discovery platform
structure based in silico drug design & A/

ACS Medicinal
Chemistry Letters



Micar21 Pipeline

18 novel drug small molecules for 2Y in 7
therapeutic areas

Micar21 Drug Discovery Platform



A fully integrated spectrum of expertise for rational drug discovery.

We are an early stage drug discovery and development biotechnology company fuelled by a suite of disruptive technologies to advance innovative medicines for the treatment of **diseases** with unmet medical need.

An **improved**
3D Crystal Structure

Novel
Virtual Screening
Approach

An **improved**
FEP+

Preclinical study
Novel advanced
prediction ADMET

Pre-Clinical IND Enabling Phase I - IV Marketing



What's next in Pre-Clinical?

Quantity available of API-need to scale up? How much?

Fast track ADME proof of concept studies

Fast track preparation of clinical protocol


Fast track preparation of first in human/ Phase I

IND (Investigation New Drug application)

Envisaged Roadmap



Clinical proof-of-concept is a key value-creation step in the clinical development of our novel medicinal product



Micar21 Pipeline



- Put Bulgaria on the world health map
- Bulgaria solves the current pandemic world health problem
- COVID-19 cured by Micar21

Micar21 Pipeline

MIC4578 Chronic Pain (Preclinical)
MIC9211 Alcoholism: AUD (Lead optimization)
MIC6479 Pancreatic Cancer (Preclinical)
MIC6701 Colorectal cancer (Lead optimization)
MIC2091 Cardiomyopathy (Hit to Lead)
MIC8411 Melasma(Hyperpigmentation) (Preclinical)
MIC2211 Hyperekplexia (Hit to Lead)
MIC2231 Stiff PS (Hit to Lead)
MIC2634 Iminoglycinuria (Hit to Lead)
MIC8471 Acne (Preclinical)
MIC5002 Cardiovascular (Preclinical)
MIC5022 Psoriasis (Preclinical)
MIC5126 Arthritis (Preclinical)
MIC1045 Oncology metastasis
MIC1936 Longevity
MIC7777 Coronaviruses & Flu
etc

Business Model & Roadmap



I. Discovering and developing novel drug candidate from Scratch till Preclinical phase with Non-Clinical "PoC" and then **Licensing/Exit** or founding **new spin out company**.

II. Discovering and developing drug molecule until **Phase 2a "PoC"** and then **Licensing/Exit**





>190 scientific publications



Micar21

Micar21 has 7 scientific publications published by:

Micar21 technology is published by:

nature

ACS Medicinal
Chemistry Letters

SCIENTIFIC
REPORTS

PCCP
Physical Chemistry Chemical Physics

ASBMB
American Society for Biochemistry and Molecular Biology

J | A | C | S
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

JOURNAL OF
CHEMICAL INFORMATION
AND MODELING

International Journal of
Molecular Sciences

molecular
pharmaceutics

PROTEINS
STRUCTURE • FUNCTION • BIOINFORMATICS

BMC
Structural Biology

ACS
Chemistry for Life



Micar21 Strategic Partners



Micar21



REPUBLIC OF BULGARIA
Ministry of Economy



BULGARIAN SMALL AND MEDIUM ENTERPRISES
PROMOTION AGENCY (BSMEPA)



BULGARIAN INDUSTRIAL ASSOCIATION
UNION OF THE BULGARIAN BUSINESS
MEMBER OF BUSINESSEUROPE

BESCO

Bulgarian Startup Association



MEDICAL
UNIVERSITY
OF PLOVDIV


AI | BULGARIA




В подкрепа на бизнеса



SOFIA UNIVERSITY
ST. KLIMENT OHRIDSKI



HEALTH & LIFE SCIENCES
CLUSTER





Micar21 in World analytic reports

COMPETITORS



Micar21

Micar21, is one of the world's 130 companies in
Deep Knowledge Analytics report.

AI for Drug Discovery Landscape 2018, 2019, 2020

Source: <https://www.dka.global/>



Micar21, is one of the world's 198 companies in
Roots Analysis Study report.

"In Silico/Computer-Aided Drug Discovery Services Market 2020-2030"

Source: https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

Micar21, is one of the world's 250 companies in
Roots Analysis Study report.

"Computer-Aided Drug Discovery Services Market 2018-2030"

Source: https://www.rootsanalysis.com/reports/view_document/computer-aided-drug-discovery-services-market-2018-2030/207.html

Intellectual property



Intellectual property is the cornerstone of our business and keeps the business more than 20 years unique and profitable.



Details for our IP's you can talk with
IP lawyer companies in different markets



7 awards for 2 Y



Micar21



**Investor of the
year 2018**



**Innovative Enterprise of
the Year**

Best Biotech Startup



Health & Life Sciences Cluster Bulgaria
*Chairman of Management Board,
Co-Founder*



AI Cluster Bulgaria
*Member of Management Board,
Co-Founder*



Bulgarian Employers Association Innovative
Technology (Brait)
*Member of Managing Board,
Co-Founder*



Bulgarian Bioscience Society
*Member of Managing Board,
Co-Founder*



Team



Dimitar Dimitrov
CEO, Co-Founder



Filip Fratev PhD
CSO, Co-Founder



Mill Greenberg
CBDO



Kristina Eskenazi
Communication



Apolo
Co-Founder



Micar21



Bolka
Pharmaceuticals



ENZYME2
Pharmaceuticals




HEMOKIN

Micar21 – Investment opportunity



ENZYME2

spin off company



Micar Innovation
Drug Discovery Factory
for novel drug molecules





novel drug molecule for the treatment of
Coronaviruses (Covid-19) & Flu
(by using first in class GlyT2 & CCR7)

Looking for funding

4 mln EUR (30% shares)

6 months project - **Until Clinical Phase 1**

Connections Covid19-ACE2-SLC6A19



Micar21 - 3 ways/approaches-Coronavirus



01.01.2020 – 12.03.2020

Different scientific journals

CCR5/CCR7

Repurpose our proprietary dual acting first in class CCR5/7 molecules

R & D activities optimize strong CCR7 antagonist. The approach: develop CCR7 antagonist with double potency, once as an sole inhibitor and second time as a CCR5 inhibitor.

24.02.2020

Cell Discovery

DOI: <https://doi.org/10.1038/s41421-020-0147-1>

ACE2

New ACE2 allosteric ligands as treatment for COVID-19

R & D activities to optimize suitable and specific inhibitor, who will stop ACE2 connecting with COVID-19

09.03.2020

Science

DOI: [10.1126/science.abb2762](https://doi.org/10.1126/science.abb2762)

SLC6A19

Repurpose our proprietary first in class SLC6A5 molecules

Micar21 have already in place strong candidate named SLC6A5. Further R & D efforts are needed to optimize the SLC6A19 candidate until clinic.

(Micar21 ACS Med Chem Lett. 2019 May 22;10(6):904-910)

Enzyme2 fighting Coronaviruses (Covid-19)


by using 3 approaches for novel drug small molecules

Repurpose our first in class molecules in CCR5/CCR7 antagonists and SLC6A5 proprietary inhibitors and optimize our new ACE2 allosteric binders for the treatment of all patients affected by COVID-19 and other related coronaviruses.

Micar21 – Investment opportunity



spin off company



Micar Innovation
Drug Discovery Factory
for novel drug molecules

novel drug molecule for the treatment of **Chronic Pain**

(first in class, best in class GlyT2, now we optimize and synthesize Lead)

Looking for funding

2.5 mln EUR (25% shares)


15 months project - Until Clinical Phase 1

Micar21 – Investment opportunity



HEMOKIN

spin off company



Micar Innovation

Drug Discovery Factory
for novel drug molecules

novel drug molecule for the treatment of
Cancer Metastatic Lymph Nodes

(+ indications for Psoriasis & Rheumatoid arthritis /CCR7 – first in class/)

Looking for funding

2.5 mln EUR (25% shares)

15 months project – Until Clinical Phase 1

Micar21 – Investment opportunity



Micar Innovation
Drug Discovery Factory
for novel drug molecules

Micar21 Drug Discovery Optimization for

CCR3, CCR6, CCR8, CCR10

(we have Leads & waiting **fourth** biological test– next 1-3 weeks)

Looking for investment & partnership

Micar21 – Investment opportunity



Micar Innovation
Drug Discovery Factory
for novel drug molecules

Micar21 Drug Discovery Optimization for **CRHR2**

(we have Leads & waiting **fourth** biological test – next 1-3 weeks)

Looking for investment & partnership


Micar21 – Investment opportunity



PANCREATIC

Pharmaceuticals

spin off company



Micar Innovation
Drug Discovery Factory
for novel drug molecules

novel drug molecules for the treatment of

Pancreatic cancer

(combination between CCR7 & SLC6A14)

Looking for funding


2.5 mln EUR (25% shares)

15 months project - Until **Clinical Phase 1**

Micar21 – Investment opportunity



spin off company



Micar Innovation
Drug Discovery Factory
for novel drug molecules

Discover **110 novel drug molecules** for all
110 known genetic mutations, associated with
Breast Cancer

Looking for funding


6.5 mln EUR (20% shares)

30 months project - Until Preclinical Phase

Micar21 – Investment opportunity



spin off company



Micar Innovation
Drug Discovery Factory
for novel drug molecules

Discover **110 novel drug molecules** for
110 known genetic mutations, associated with
110 Rare Diseases

Looking for funding

Internal programme

30 months project – Until Preclinical Phase



Micar21

Thank you for your attention!

A fully integrated spectrum of expertise for rational drug discovery.

We are an early stage drug discovery and development biotechnology company fuelled by a suite of disruptive technologies to advance innovative medicines for the treatment of diseases with high unmet medical need.

Dimitar Dimitrov
dimitar@Micar21.com
www.Micar21.com